Loading...

World-Class Retina Care. Community-Based Caring.

Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema

Posted On October 9, 2024 / By / Posted in Blog

Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema

Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,

read more
Posted On August 29, 2024 / By / Posted in Blog

Offices Closed for Labor Day on 9/2/24

All Texas Retina Associates offices will be closed on Monday, September 2, 2024, in observance of Labor Day. We wish everyone a safe and happy holiday weekend!

read more
Posted On August 28, 2024 / By / Posted in Blog

Dr. Abbey Discusses Cataract Surgery in Patients with AMD on New Podcast Episode

Cataracts and age-related macular degeneration (AMD) are two of the most common eye conditions. Texas Retina’s Ashkan Abbey, MD, was recently invited to participate in the latest episode of “Blind Spot –

read more
Posted On August 15, 2024 / By / Posted in Blog

Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease

Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for

read more
Posted On August 13, 2024 / By / Posted in Blog

Can Ozempic Affect Your Eyes or Vision?

Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a

read more
Posted On August 6, 2024 / By / Posted in Blog

Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma

The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated

read more
Posted On August 2, 2024 / By / Posted in Blog

Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial

On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific

read more
Posted On July 30, 2024 / By / Posted in Blog

Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting

Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting

read more
Posted On July 17, 2024 / By / Posted in Blog

July is UV Safety Month — Debunking Seven Common Myths About Sunglasses

When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July

read more
Posted On May 9, 2024 / By / Posted in Blog

Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology

At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand

read more